Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception

Eyup Akgun, Muhammad I. Javed, Mary M. Lunzer, Branden A. Smeester, Al J Beitz, Philip S Portoghese

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The low effectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammatory pain is a result of opioid-induced release of proinflammatory cytokines and glutamate that lower the pain threshold. In this regard, the use of opioids with metabotropic glutamate-5 receptor (mGluR 5) antagonist has been reported to increase the efficacy of morphine and prevent the establishment of adverse effects during chronic use. Given the presence of opioid receptors (MORs) and mGluR5 in glia and neurons, together with reports that suggest coexpressed MOR/mGluR5 receptors in cultured cells associate as a heteromer, the possibility that such a heteromer could be a target in vivo was addressed by the design and synthesis of a series of bivalent ligands that contain mu opioid agonist and mGluR 5 antagonist pharmacophores linked through spacers of varying length (10-24 atoms). The series was evaluated for antinociception using the tail-flick and von Frey assays in mice pretreated with lipopolysaccharide (LPS) or in mice with bone cancer. In LPS-pretreated mice, MMG22 (4c, 22-atom spacer) was the most potent member of the series (intrathecal ED50 ∼9 fmol per mouse), whereas in untreated mice its ED50 was more than three orders of magnitude higher. As members of the series with shorter or longer spacers have ≥500-fold higher ED50s in LPS-treated mice, the exceptional potency of MMG22 may be a result of the optimal bridging of protomers in a putative MOR-mGluR5 heteromer. The finding that MMG22 possesses a >10 6 therapeutic ratio suggests that it may be an excellent candidate for treatment of chronic, intractable pain via spinal administration.

Original languageEnglish (US)
Pages (from-to)11595-11599
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number28
DOIs
StatePublished - Jul 9 2013

Fingerprint

Ligands
Pain
Opioid Analgesics
Lipopolysaccharides
Chronic Pain
Morphine
Metabotropic Glutamate 5 Receptor
Intractable Pain
Bone Neoplasms
Pain Threshold
Protein Subunits
Opioid Receptors
Neuroglia
Tail
Glutamic Acid
Cultured Cells
Therapeutics
Cytokines
Neurons

Keywords

  • MPEP
  • Respiratory depression
  • Tolerance

Cite this

Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception. / Akgun, Eyup; Javed, Muhammad I.; Lunzer, Mary M.; Smeester, Branden A.; Beitz, Al J; Portoghese, Philip S.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 28, 09.07.2013, p. 11595-11599.

Research output: Contribution to journalArticle

@article{aa3c3b5d97814e79977a7811e8ff5e91,
title = "Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception",
abstract = "The low effectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammatory pain is a result of opioid-induced release of proinflammatory cytokines and glutamate that lower the pain threshold. In this regard, the use of opioids with metabotropic glutamate-5 receptor (mGluR 5) antagonist has been reported to increase the efficacy of morphine and prevent the establishment of adverse effects during chronic use. Given the presence of opioid receptors (MORs) and mGluR5 in glia and neurons, together with reports that suggest coexpressed MOR/mGluR5 receptors in cultured cells associate as a heteromer, the possibility that such a heteromer could be a target in vivo was addressed by the design and synthesis of a series of bivalent ligands that contain mu opioid agonist and mGluR 5 antagonist pharmacophores linked through spacers of varying length (10-24 atoms). The series was evaluated for antinociception using the tail-flick and von Frey assays in mice pretreated with lipopolysaccharide (LPS) or in mice with bone cancer. In LPS-pretreated mice, MMG22 (4c, 22-atom spacer) was the most potent member of the series (intrathecal ED50 ∼9 fmol per mouse), whereas in untreated mice its ED50 was more than three orders of magnitude higher. As members of the series with shorter or longer spacers have ≥500-fold higher ED50s in LPS-treated mice, the exceptional potency of MMG22 may be a result of the optimal bridging of protomers in a putative MOR-mGluR5 heteromer. The finding that MMG22 possesses a >10 6 therapeutic ratio suggests that it may be an excellent candidate for treatment of chronic, intractable pain via spinal administration.",
keywords = "MPEP, Respiratory depression, Tolerance",
author = "Eyup Akgun and Javed, {Muhammad I.} and Lunzer, {Mary M.} and Smeester, {Branden A.} and Beitz, {Al J} and Portoghese, {Philip S}",
year = "2013",
month = "7",
day = "9",
doi = "10.1073/pnas.1305461110",
language = "English (US)",
volume = "110",
pages = "11595--11599",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "28",

}

TY - JOUR

T1 - Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception

AU - Akgun, Eyup

AU - Javed, Muhammad I.

AU - Lunzer, Mary M.

AU - Smeester, Branden A.

AU - Beitz, Al J

AU - Portoghese, Philip S

PY - 2013/7/9

Y1 - 2013/7/9

N2 - The low effectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammatory pain is a result of opioid-induced release of proinflammatory cytokines and glutamate that lower the pain threshold. In this regard, the use of opioids with metabotropic glutamate-5 receptor (mGluR 5) antagonist has been reported to increase the efficacy of morphine and prevent the establishment of adverse effects during chronic use. Given the presence of opioid receptors (MORs) and mGluR5 in glia and neurons, together with reports that suggest coexpressed MOR/mGluR5 receptors in cultured cells associate as a heteromer, the possibility that such a heteromer could be a target in vivo was addressed by the design and synthesis of a series of bivalent ligands that contain mu opioid agonist and mGluR 5 antagonist pharmacophores linked through spacers of varying length (10-24 atoms). The series was evaluated for antinociception using the tail-flick and von Frey assays in mice pretreated with lipopolysaccharide (LPS) or in mice with bone cancer. In LPS-pretreated mice, MMG22 (4c, 22-atom spacer) was the most potent member of the series (intrathecal ED50 ∼9 fmol per mouse), whereas in untreated mice its ED50 was more than three orders of magnitude higher. As members of the series with shorter or longer spacers have ≥500-fold higher ED50s in LPS-treated mice, the exceptional potency of MMG22 may be a result of the optimal bridging of protomers in a putative MOR-mGluR5 heteromer. The finding that MMG22 possesses a >10 6 therapeutic ratio suggests that it may be an excellent candidate for treatment of chronic, intractable pain via spinal administration.

AB - The low effectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammatory pain is a result of opioid-induced release of proinflammatory cytokines and glutamate that lower the pain threshold. In this regard, the use of opioids with metabotropic glutamate-5 receptor (mGluR 5) antagonist has been reported to increase the efficacy of morphine and prevent the establishment of adverse effects during chronic use. Given the presence of opioid receptors (MORs) and mGluR5 in glia and neurons, together with reports that suggest coexpressed MOR/mGluR5 receptors in cultured cells associate as a heteromer, the possibility that such a heteromer could be a target in vivo was addressed by the design and synthesis of a series of bivalent ligands that contain mu opioid agonist and mGluR 5 antagonist pharmacophores linked through spacers of varying length (10-24 atoms). The series was evaluated for antinociception using the tail-flick and von Frey assays in mice pretreated with lipopolysaccharide (LPS) or in mice with bone cancer. In LPS-pretreated mice, MMG22 (4c, 22-atom spacer) was the most potent member of the series (intrathecal ED50 ∼9 fmol per mouse), whereas in untreated mice its ED50 was more than three orders of magnitude higher. As members of the series with shorter or longer spacers have ≥500-fold higher ED50s in LPS-treated mice, the exceptional potency of MMG22 may be a result of the optimal bridging of protomers in a putative MOR-mGluR5 heteromer. The finding that MMG22 possesses a >10 6 therapeutic ratio suggests that it may be an excellent candidate for treatment of chronic, intractable pain via spinal administration.

KW - MPEP

KW - Respiratory depression

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84879966473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879966473&partnerID=8YFLogxK

U2 - 10.1073/pnas.1305461110

DO - 10.1073/pnas.1305461110

M3 - Article

VL - 110

SP - 11595

EP - 11599

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 28

ER -